Agents for improving or preventing cardiotoxicity and autophagy abnormality-related conditions caused by anticancer drugs

摘要

PROBLEM TO BE SOLVED: To provide a new drug for improving or preventing cardiotoxicity caused by an anticancer drug. SOLUTION: By using an eosinophil cationic protein (ECP) in combination with an anticancer agent, or by administering the anticancer agent before or after administration, the cardiotoxicity of the anticancer agent can be improved or prevented. When the agent of the present invention is used in combination with an anticancer agent that causes cardiotoxicity, the dose, administration target, target disease / sex / age, administration method, administration period, administration frequency, and applicable disease of the anticancer agent are restricted. Can be alleviated or eliminated, and it is possible to effectively improve or prevent cancer in more patients. Furthermore, as an embodiment of the present invention, administration of an eosinophil cationic protein (ECP) suppresses the expression of the Atg5 and Bnip3 genes that promote autophagy, and improves or prevents autophagy abnormality-related states. can do. [Selection diagram] Fig. 2